For COVID-19 Convalescent Plasma Program Requirements Click Here!
News & Views
Newsletters
Donate
Contact
Search
Close
News & Views
Newsletters
Donate
Contact
Search
Close
About
About Us
Mission, Vision, Core Values
Centers of Excellence
Research Operations
Office of Human Research Protection Program
Office of Clinical Research Coordination
Office of Grants & Contract Management
DHR Research Academy
Research Partnerships & Affiliations
Partnerships & Affiliations
Partner With Us
Sponsors
Core Facilities
For Research Patients
General Information
Clinical Trials
Para Pacientes
Información General
Ensayos Clínicos
For Investigators
For Industry Sponsors
Knowledge Center
Become A Research Patient
Menu
About
About Us
Mission, Vision, Core Values
Centers of Excellence
Research Operations
Office of Human Research Protection Program
Office of Clinical Research Coordination
Office of Grants & Contract Management
DHR Research Academy
Research Partnerships & Affiliations
Partnerships & Affiliations
Partner With Us
Sponsors
Core Facilities
For Research Patients
General Information
Clinical Trials
Para Pacientes
Información General
Ensayos Clínicos
For Investigators
For Industry Sponsors
Knowledge Center
Become A Research Patient
Menu
About
About Us
Mission, Vision, Core Values
Centers of Excellence
Research Operations
Office of Human Research Protection Program
Office of Clinical Research Coordination
Office of Grants & Contract Management
DHR Research Academy
Research Partnerships & Affiliations
Partnerships & Affiliations
Partner With Us
Sponsors
Core Facilities
For Research Patients
General Information
Clinical Trials
Para Pacientes
Información General
Ensayos Clínicos
For Investigators
For Industry Sponsors
Knowledge Center
Become A Research Patient
Donate
5323 S. McColl Rd., Edinburg, TX 78539
dhrresearch@dhr-rgv.com
(956) 362-2390
Trial Category: Endocrinology/Gastroenterology
Results
Optimal Therapeutic Dosing Scheme in Thyroid Hormone Replacement After Thyroidectomy for Benign Disease: Retrospective Review and Validation Study
View Details →
A 26-Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26-Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age
View Details →
Minimizing narcotic analgesia after endocrine surgery
View Details →
Adrenal Disease Database
View Details →
Impact of home telemonitoring on the management of patients with diabetes and hypertension
View Details →
The Effectiveness of Bariatric Surgery on Metabolic Profiles in a Hispanic Population including Effectiveness of Early Preoperative Weight Loss as a Predictor of the Surgical Success
View Details →
Osteoporosis-Related Post-Fracture Care Application Development and Testing
View Details →
A Nine Week Open-Label Crossover Study of Insulin Degludec (U100 and U200) and Insulin Glargine (U300) to Observe and Compare the Incidence of Hypoglycemia when Basal Insulin Administration is Changed from Evening to Morning.
View Details →
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 2
View Details →
A Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601D with NovoLog® in Type 1 Diabetes Mellitus Patients
View Details →
